Samagya Banskota

Samagya Banskota’s work on viruslike particles (VLPs) represents a quiet but profound shift in how we deliver therapies, one that could redefine medicine’s reach in an era where precision and safety are paramount. While gene therapy and mRNA vaccines have dominated headlines, VLPs offer a middle ground—combining the efficiency of viral vectors with the reduced risk of synthetic delivery systems. For patients with genetic disorders, neurodegenerative diseases, or even certain cancers, this approach could mean treatments that are not just more targeted but also more accessible, bypassing some of the immune complications that have long plagued viral delivery methods. Banskota’s focus on safety aligns with a growing demand for therapies that minimize off-target effects, a concern that has slowed progress in fields like CRISPR-based treatments. Her background in a family of physicians in Nepal adds a layer of significance to her research. The contrast between high-resource medical systems and those in developing nations like Nepal underscores a critical point: innovations in drug delivery don’t just improve outcomes—they can democratize access. VLPs, if scalable, could be particularly impactful in regions where cold-chain storage and complex dosing regimens are barriers to care. The challenge now is proving that these particles can perform consistently in large-scale production, a hurdle that has tripped up many promising biotech solutions. What remains uncertain is how quickly VLPs will move from lab bench to clinic. Regulatory pathways for non-viral delivery systems are still evolving, and questions linger about long-term stability and potential unintended interactions with the immune system. Meanwhile, competition from other delivery methods, like lipid nanoparticles, means Banskota’s work will need to demonstrate clear advantages to secure funding and adoption. At a broader level, her research fits into a larger reckoning with how we design therapies for the 21st century—balancing innovation with equity. If successful, VLPs could bridge the gap between cutting-edge science and real-world medicine, proving that sometimes, the most transformative breakthroughs aren’t the ones that make headlines, but the ones that make healing possible.